Cancer discovery news
Our researchers are making the discoveries that defeat cancer. Read the latest findings from our world-leading research.
Visit our main news hub to read about news on new funding, our fundraising activities and much more. If you want to keep updated on our news, you can follow us on social media or sign up for our Search newsletter.
If you’re a journalist and want to find out more, you can contact our media relations team.
-16-9.jpg?sfvrsn=b9495114_2 "Glioblastoma cells (Dr Chris Jones/the ICR) 16:9")
ICR plays key role in groundbreaking new brain cancer trials
Scientists from The Institute of Cancer Research (ICR), London, are taking part in a groundbreaking new set of brain cancer clinical trials designed to improve survival and quality of life for people with glioblastoma.
-growing-in-single-files-along-collagen-fibres-(red)_renee-flaherty.jpg?sfvrsn=b3bf3bc8_3 "Invasive lobular breast cells (yellow) growing in single files along collagen fibres (red)_Renee Flaherty")
Scientists identify a potential new treatment option for lobular breast cancer
A drug currently being tested in clinical trials for a rare blood cancer could also be used to treat lobular breast cancer, according to a study published in the journal Cancer Research.
Scientists develop new way to determine which patients will respond best to bowel cancer treatment
Scientists have developed an AI-powered method that could determine which patients with advanced bowel cancer are most likely to respond to a targeted drug used on the NHS – potentially sparing thousands of patients from treatments that won’t work for them.
UK scientists create most detailed map yet of mutations that drive cancer
Scientists have created the most comprehensive map to date of the genetic mutations that fuel cancer – opening the door to extending precision treatments to thousands more patients and offering clues as to why bowel cancer rates are rising in younger people.
ICR scientists support promising new immunotherapy trial for advanced ovarian cancer
Scientists at The Institute of Cancer Research, London, are supporting an international clinical trial of a promising new immunotherapy treatment for advanced ovarian cancer.
New study reveals key enzyme as hidden driver of cancer stress responses
An important study has uncovered an unexpected molecular player that helps make cancer cells stress-resilient, thereby promoting the survival, growth and progression of cancer.
Scientists discover new avenue for treating an aggressive form of breast cancer
A gene that is typically active only in reproductive cells may hold the key to new treatments for triple negative breast cancer, according to new research by scientists at The Institute of Cancer Research, London
Immunotherapy uses invisibility cloak to deliver direct hit to prostate cancer
A new immunotherapy drug has shown promise for safely treating prostate cancer, a phase I trial reports.
.jpg?sfvrsn=205a5de0_2 "Castration resistant prostate cancer cells stained for a number of key driver molecules. (Mateus Crespo, Gerhardt Attard and Johann de Bono / the ICR, 2012)")
Targeted radiotherapy injection shrinks treatment-resistant prostate cancer tumours in early clinical trial
A new drug for prostate cancer, which delivers a precisely targeted dose of radiation to cancer cells, can keep cancer at bay, a phase I trial reports.
Researchers overcome major obstacle in targeted protein degradation
In a significant advancement, cancer researchers have found a long-sought way to overcome a critical design barrier in the generation of small-molecule chemical tools and drugs that work by targeted protein degradation.
New study shows promise for more reliable imaging of an important tumour characteristic
A team of scientists at The Institute of Cancer Research, London, has developed a repeatable three-dimensional (3D) imaging technique that could transform preclinical cancer studies.
New strategy targets “undruggable” protein in T-cell leukaemia, triggering cancer cell death
Scientists have unveiled a ground-breaking approach to tackling one of cancer biology’s most elusive targets: the protein LMO2, a key driver of T-cell acute lymphoblastic leukaemia (T-ALL).